Rapid subacute myelopathy following kidney transplantation from HTLV-1 donors: role of immunosuppresors and failure of antiretrovirals.
Lourdes RocCarmen de MendozaMiriam Fernández-AlonsoGabriel ReinaVicente Sorianonull nullPublished in: Therapeutic advances in infectious disease (2019)
Two kidney transplant recipients from a single donor became infected with HTLV-1 (human T-lymphotropic virus type 1) in Spain. One developed myelopathy 8 months following surgery despite early prescription of antiretroviral therapy. The allograft was removed from the second recipient at month 8 due to rejection and immunosuppressors discontinued. To date, 3 years later, this patient remains infected but asymptomatic. HTLV-1 infection was recognized retrospectively in the donor, a native Spaniard who had sex partners from endemic regions. Our findings call for a reappraisal of screening policies on donor-recipient organ transplantation. Based on the high risk of disease development and the large flux of persons from HTLV-1 endemic regions, pre-transplant HTLV-1 testing should be mandatory in Spain.
Keyphrases
- kidney transplantation
- antiretroviral therapy
- spinal cord
- minimally invasive
- endothelial cells
- public health
- hiv infected
- human immunodeficiency virus
- stem cells
- hiv aids
- hiv infected patients
- bone marrow
- coronary artery disease
- hiv positive
- pluripotent stem cells
- spinal cord injury
- mesenchymal stem cells
- hepatitis c virus
- sensitive detection
- disease virus
- loop mediated isothermal amplification